FDA Panel Says Breast Transilluminators Should Remain Class III
This article was originally published in The Gray Sheet
FDA’s Radiological Devices Panel recommends that pre-amendment breast transilluminator devices should stay as class III devices.
You may also be interested in...
CDRH is proposing to require PMAs for four categories of devices for the first time, but it is not likely to hear much resistance from industry
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.